Sanofi announces the decision of the U.S. Federal Trade Commission to seek a preliminary injunction against its proposed licensing agreement with Maze Therapeutics, announced on May 1.This agreement.
SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the U.S. Federal Trade Commission (FTC) has filed a complaint seeking to block Sanofi’s exclusive worldwide license agreement for Maze’s glycogen synthase 1 (GYS1) program, including clinical candidate MZE001, which is in development for the treatment of Pompe disease and other potential indications. The agreement was originally announced in May
Sanofi drops rare disease drug purchase after FTC files suit financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.
Sanofi SA (NASDAQ: SNY) said it is terminating the licensing agreement for Maze Therapeutics Inc.'s treatment for a rare genetic disorder after the Federal Trade Commission (FTC)
CAC 40 Edges Higher Ahead Of FOMC Meeting finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.